Plasmacytoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86855C90.2C90.3
Who is this for?
Show terms as
7Active trials25Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jan 2026CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

Affiliated Hospital to Academy of Military Medical Sciences — EARLY_PHASE1

TrialNOT YET RECRUITING
Aug 2025CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Affiliated Hospital to Academy of Military Medical Sciences — EARLY_PHASE1

TrialNOT YET RECRUITING
Aug 2025Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

Institute of Hematology & Blood Diseases Hospital, China — PHASE2

TrialRECRUITING
Aug 2025CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Chinese PLA General Hospital — EARLY_PHASE1

TrialNOT YET RECRUITING
Apr 2025GR1803 Injection in Patients With RRMM

Genrix (Shanghai) Biopharmaceutical Co., Ltd. — PHASE2

TrialRECRUITING
Feb 2025SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2

TrialRECRUITING
May 2024Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2

TrialRECRUITING
Mar 2023Longitudinal Data Registry of Plasma Cell Dyscrasia

Shanghai Zhongshan Hospital

TrialRECRUITING
Apr 2022Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Peking Union Medical College Hospital — PHASE2

TrialRECRUITING
Nov 2019A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Memorial Sloan Kettering Cancer Center — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Plasmacytoma.

7 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

7 recruitingView all trials with filters →
Phase 31 trial
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Phase 3
Active
PI: Roger Owen (St James's University Hospital) · Sites: Bath; Blackpool +11 more · Age: 1899 yrs
Phase 25 trials
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
Phase 2
Active
· Sites: Athens; Thessaloniki +6 more · Age: 1899 yrs
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Phase 2
Actively Recruiting
· Sites: Beijing · Age: 1880 yrs
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Phase 2
Active
PI: Urvi Shah, MD (Memorial Sloan Kettering Cancer Center) · Sites: Basking Ridge, New Jersey; Middletown, New Jersey +5 more · Age: 1899 yrs
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Phase 2
Actively Recruiting
· Sites: Hangzhou, Zhejiang · Age: 1880 yrs
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Phase 2
Actively Recruiting
· Sites: Tianjin · Age: 1878 yrs

Specialists

25 foundView all specialists →
AM
Attaya Suvannasankha, MD
INDIANAPOLIS, IN
Specialist
PI on 2 active trials
NM
Neal Flomenberg, MD
PHILADELPHIA, PA
Specialist
PI on 5 active trials
DC
Dolores Grosso, DNP, CRNP
Specialist
PI on 4 active trials
RN
Ryotaro Nakamura
Duarte, California
Specialist

Rare Disease Specialist

PI on 6 active trials
PM
Paul Martin
Specialist
PI on 3 active trials73 Plasmacytoma publications
MM
Margarida Magalhaes-Silverman, MD
Specialist
PI on 1 active trial
AM
Angela Dispenzieri, M.D.
ROCHESTER, MN
Specialist
PI on 5 active trials
RR
Ramesh Ramanathan
PITTSBURGH, PA
Specialist
PI on 3 active trials7 Plasmacytoma publications
SK
Shaji Kumar
Anchorage, Alaska
Specialist

Rare Disease Specialist

PI on 7 active trials
SK
Susan Knox
Specialist
PI on 1 active trial
AW
Ann Woolfrey
SEATTLE, WA
Specialist
PI on 5 active trials
SM
Shebli Atrash, MD, MS
CHARLOTTE, NC
Specialist
PI on 1 active trial
TM
Tom R. Fitch, M.D.
GLENDALE, AZ
Specialist
PI on 1 active trial
TD
Tamila Kindwall-Keller, DO
Specialist
PI on 1 active trial19 Plasmacytoma publications
PM
Paul Armistead, MD
CHAPEL HILL, NC
Specialist
PI on 1 active trial
AM
Athanasios Fassas, MD
Specialist
PI on 1 active trial
SM
Susanne Gretzinger, MD
Specialist
PI on 1 active trial
HL
Hans C Lee
Specialist
PI on 1 active trial
AM
Anuj Mahindra
Specialist
PI on 1 active trial
AL
Alexander Lesokhin
NEW YORK, NY
Specialist
PI on 1 active trial
AJ
Andrzej J. Jakubowiak
CHICAGO, IL
Specialist
PI on 1 active trial
RO
Roger Owen
CHRISTINSBURG, VA
Specialist
PI on 1 active trial
US
Urvi Shah
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Plasmacytoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open PlasmacytomaForum →

No community posts yet. Be the first to share your experience with Plasmacytoma.

Start the conversation →

Latest news about Plasmacytoma

Disease timeline:

New recruiting trial: Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

A new clinical trial is recruiting patients for Plasmacytoma

New recruiting trial: Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

A new clinical trial is recruiting patients for Plasmacytoma

New recruiting trial: GR1803 Injection in Patients With RRMM

A new clinical trial is recruiting patients for Plasmacytoma

New recruiting trial: SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

A new clinical trial is recruiting patients for Plasmacytoma

New recruiting trial: The Indiana Myeloma Registry

A new clinical trial is recruiting patients for Plasmacytoma

New recruiting trial: Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

A new clinical trial is recruiting patients for Plasmacytoma

New recruiting trial: Longitudinal Data Registry of Plasma Cell Dyscrasia

A new clinical trial is recruiting patients for Plasmacytoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Plasmacytoma

Are there clinical trials for Plasmacytoma?

Yes — 7 recruiting clinical trials are currently listed for Plasmacytoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Plasmacytoma?

25 specialists and care centers treating Plasmacytoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.